pubmed-article:7805774 | rdf:type | pubmed:Citation | lld:pubmed |
pubmed-article:7805774 | lifeskim:mentions | umls-concept:C0034826 | lld:lifeskim |
pubmed-article:7805774 | lifeskim:mentions | umls-concept:C1167622 | lld:lifeskim |
pubmed-article:7805774 | lifeskim:mentions | umls-concept:C1979963 | lld:lifeskim |
pubmed-article:7805774 | lifeskim:mentions | umls-concept:C0231491 | lld:lifeskim |
pubmed-article:7805774 | lifeskim:mentions | umls-concept:C2003903 | lld:lifeskim |
pubmed-article:7805774 | lifeskim:mentions | umls-concept:C0249301 | lld:lifeskim |
pubmed-article:7805774 | pubmed:issue | 3 | lld:pubmed |
pubmed-article:7805774 | pubmed:dateCreated | 1995-1-30 | lld:pubmed |
pubmed-article:7805774 | pubmed:abstractText | The binding selectivity of the muscarinic antagonist tripitramine has been tested on the five cloned human muscarinic receptor subtypes (Hm1 to Hm5) expressed in chinese hamster ovary (CHO-K1) cells. The results indicate that tripitramine binds to the muscarinic Hm2 receptor with a Ki value of 0.27 +/- 0.02 nM. Tripitramine distinguishes Hm2 vs. Hm4 by a factor of 24 and vs. Hm3 and Hm5 by a factor of 142 and 125, respectively. A lower affinity ratio, about 6-fold, was found between muscarinic Hm2 and Hm1 receptors. A comparative study with the well-known selective muscarinic M2 receptor antagonist methoctramine indicates that tripitramine has gained both potency and selectivity for the muscarinic Hm2 receptor subtype. | lld:pubmed |
pubmed-article:7805774 | pubmed:language | eng | lld:pubmed |
pubmed-article:7805774 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7805774 | pubmed:citationSubset | IM | lld:pubmed |
pubmed-article:7805774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7805774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7805774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7805774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7805774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7805774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7805774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7805774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7805774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7805774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7805774 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
pubmed-article:7805774 | pubmed:status | MEDLINE | lld:pubmed |
pubmed-article:7805774 | pubmed:month | Aug | lld:pubmed |
pubmed-article:7805774 | pubmed:issn | 0014-2999 | lld:pubmed |
pubmed-article:7805774 | pubmed:author | pubmed-author:BarbierPP | lld:pubmed |
pubmed-article:7805774 | pubmed:author | pubmed-author:MelchiorreCC | lld:pubmed |
pubmed-article:7805774 | pubmed:author | pubmed-author:MinariniAA | lld:pubmed |
pubmed-article:7805774 | pubmed:author | pubmed-author:TedeschiDD | lld:pubmed |
pubmed-article:7805774 | pubmed:author | pubmed-author:MaggioRR | lld:pubmed |
pubmed-article:7805774 | pubmed:author | pubmed-author:BolognesiM... | lld:pubmed |
pubmed-article:7805774 | pubmed:issnType | Print | lld:pubmed |
pubmed-article:7805774 | pubmed:day | 16 | lld:pubmed |
pubmed-article:7805774 | pubmed:volume | 268 | lld:pubmed |
pubmed-article:7805774 | pubmed:owner | NLM | lld:pubmed |
pubmed-article:7805774 | pubmed:authorsComplete | Y | lld:pubmed |
pubmed-article:7805774 | pubmed:pagination | 459-62 | lld:pubmed |
pubmed-article:7805774 | pubmed:dateRevised | 2008-11-21 | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:meshHeading | pubmed-meshheading:7805774-... | lld:pubmed |
pubmed-article:7805774 | pubmed:year | 1994 | lld:pubmed |
pubmed-article:7805774 | pubmed:articleTitle | Binding profile of the selective muscarinic receptor antagonist tripitramine. | lld:pubmed |
pubmed-article:7805774 | pubmed:affiliation | Institute of Pharmacology School of Medicine, University of Pisa, Italy. | lld:pubmed |
pubmed-article:7805774 | pubmed:publicationType | Journal Article | lld:pubmed |
pubmed-article:7805774 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7805774 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7805774 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7805774 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7805774 | lld:pubmed |
http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:7805774 | lld:pubmed |